Filing Flows › Vanda Pharmaceuticals (VNDA) › R&D spending
Vanda Pharmaceuticals (VNDA) R&D spending by quarter
Vanda Pharmaceuticals' R&D spending was $27.6M in Q3 2026 (third quarter 2026), -25% from Q2 2026. Over the last 7 quarters it ranged from $22.0M (Q2 2025) to $37.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $27.6M | -25% | +22% |
| Q2 2026 | $37.0M | +30% | +68% |
| Q1 2026 | $28.4M | -2% | -20% |
| Q4 2025 | $29.0M | +29% | — |
| Q3 2025 | $22.6M | +3% | — |
| Q2 2025 | $22.0M | -38% | — |
| Q1 2025 | $35.7M | — | — |
Q3 2026 at a glance
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vanda Pharmaceuticals' R&D spending?
Vanda Pharmaceuticals' R&D spending was $27.6M in Q3 2026 (third quarter 2026), -25% from Q2 2026.
How has Vanda Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $22.0M (Q2 2025) to $37.0M (Q2 2026).